Deals this week: InSphero, Ind-Swift Laboratories, Sage Therapeutics

15th June 2018 (Last Updated June 15th, 2018 00:00)

InSphero has raised $10m in a funding round provided by internal and external investors.

InSphero has raised $10m in a funding round provided by internal and external investors.

The funding round was led by Dr. Jurg Gysi, former GM of Promega.

The latest funding brings the total proceeds raised by the company to $35m.

Based in Switzerland, InSphero is a drug discovery and testing company and a developer of 3D InSight micro-tissues.

The company plans to use the funds towards the development of its discovery platforms for metabolic diseases such as Type 1 and Type 2 diabetes, liver diseases, and other diseases such as cancer.

Contract research and manufacturing company Ind-Swift Laboratories has raised Rs4.25tr ($62bn) through the issuance of redeemable non-convertible debentures to two investors at an interest rate of 10%.

Ind-Swift has issued more than 4,245 debentures to ECAP Equities and ECL Finance as part of the transaction.

All companies involved in the transaction are based in India.

"StrideBio has raised $15.7m through a series A funding round provided by Hatteras Venture Partners."

StrideBio has raised $15.7m through a series A funding round provided by Hatteras Venture Partners.

The funding round included participation from Takeda Ventures, UCB Ventures, and Alexandria Venture Investments.

StrideBio is a developer of engineered viral vectors for gene therapy for the treatment of rare diseases.

All companies involved in the transaction are based in the US.

StrideBio plans to use the funds to advance its Transformational AAV Platform, as well as other multiple clinical programmes.

Genomma Lab USA has completed the acquisition of Cheracol D and Rose Milk brands from Sheffield Pharmaceuticals.

Simultaneously, Genomma has purchased Bufferin brand from Dr. Reddy’s Laboratories for $3.02m.

Based in the US, Genomma is a provider of pharmaceutical over the counter (OTC) drugs and generic drugs, while Sheffield Pharmaceuticals, also based in the US, is a producer and distributor of OTC pharmaceutical products.

The acquisition enables Genomma to fortify its marketing and distribution capabilities and expand its footprint in the United States OTC market.